Items where authors include "Boleti, E."

Article

Pan, X., AbdulJabbar, K. orcid.org/0000-0002-4411-4435, Coelho-Lima, J. et al. (276 more authors) (2024) The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Nature Cancer. ISSN 2662-1347

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Ng, K.W., Boumelha, J., Enfield, K.S.S. orcid.org/0000-0002-4551-6073 et al. (328 more authors) (2023) Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature, 616. pp. 563-573. ISSN 0028-0836

Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565, Black, J.R.M., Puttick, C. et al. (294 more authors) (2023) Genomic–transcriptomic evolution in lung cancer and metastasis. Nature, 616. pp. 543-552. ISSN 0028-0836

Abbosh, C. orcid.org/0000-0002-8983-1382, Frankell, A.M. orcid.org/0000-0002-0341-7878, Harrison, T. et al. (303 more authors) (2023) Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature, 616 (7957). pp. 553-562. ISSN 0028-0836

Frankell, A.M. orcid.org/0000-0002-0341-7878, Dietzen, M. orcid.org/0000-0002-6853-7563, Al Bakir, M. orcid.org/0000-0002-0846-8332 et al. (284 more authors) (2023) The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature, 616. pp. 525-533. ISSN 0028-0836

Al Bakir, M. orcid.org/0000-0002-0846-8332, Huebner, A. orcid.org/0000-0001-8009-4999, Martínez-Ruiz, C. orcid.org/0000-0002-4817-0565 et al. (283 more authors) (2023) The evolution of non-small cell lung cancer metastases in TRACERx. Nature, 616. pp. 534-542. ISSN 0028-0836

Hill, W., Lim, E.L., Weeden, C.E. et al. (323 more authors) (2023) Lung adenocarcinoma promotion by air pollutants. Nature, 616 (7955). pp. 159-167. ISSN 0028-0836

Al-Sawaf, O. orcid.org/0000-0001-9895-0570, Weiss, J., Skrzypski, M. et al. (302 more authors) (2023) Body composition and lung cancer-associated cachexia in TRACERx. Nature Medicine, 29 (4). pp. 846-858. ISSN 1078-8956

Karasaki, T. orcid.org/0000-0001-6863-2360, Moore, D.A. orcid.org/0000-0002-6296-1312, Veeriah, S. et al. (288 more authors) (2023) Evolutionary characterization of lung adenocarcinoma morphology in TRACERx. Nature Medicine, 29 (4). pp. 833-845. ISSN 1078-8956

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Powles, T., Brown, J., Larkin, J. et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534